Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men
Open Access
- 1 January 2011
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (1), 150-158
- https://doi.org/10.1210/jc.2010-1587
Abstract
Context and Objective: Strategies to augment pulsatile GH may be beneficial in patients with excess visceral adiposity, in whom GH secretion is reduced. The objective of this study was to determine the effects of a novel GHRH (GHRH1–44) analog, tesamorelin, on endogenous GH pulsatility and insulin sensitivity in healthy men. Design, Participants, and Intervention: Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m2) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal. Outcome Measures: The primary end point was change in mean overnight GH as determined by overnight frequent sampling. Secondary end points included insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; IGF-I; and GH secretion parameters, including pulse area, pulse frequency, and basal secretion. Results: Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log10 GH peak area (change +0.4 ± 0.1 log10 μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008). IGF-I increased by 181 ± 22 μg/liter (P < 0.0001). Neither fasting glucose (P = 0.93) nor insulin-stimulated glucose uptake (P = 0.61) was significantly affected by tesamorelin. Conclusions: Once-daily short-term treatment with a GHRH1–44 analog, tesamorelin, augments basal and pulsatile GH secretion. Moreover, although tesamorelin significantly increases IGF-I, peripheral insulin-stimulated glucose uptake appears to be preserved.Keywords
This publication has 43 references indexed in Scilit:
- Growth Hormone Deficiency by Growth Hormone Releasing Hormone-Arginine Testing Criteria Predicts Increased Cardiovascular Risk Markers in Normal Young Overweight and Obese WomenJournal of Clinical Endocrinology & Metabolism, 2008
- Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIVNew England Journal of Medicine, 2007
- Growth Hormone Regulation of Sex-Dependent Liver Gene ExpressionMolecular Endocrinology, 2006
- Truncal Adiposity, Relative Growth Hormone Deficiency, and Cardiovascular RiskJournal of Clinical Endocrinology & Metabolism, 2005
- Down-Regulation of Liver JAK2-STAT5b Signaling by the Female Plasma Pattern of Continuous Growth Hormone StimulationMolecular Endocrinology, 1999
- Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure1Journal of Clinical Endocrinology & Metabolism, 1997
- Effects of single nightly injections of growth hormone—releasing hormone (GHRH 1–29) in healthy elderly menMetabolism, 1997
- Effects of pulsatile delivery of basal growth hormone on lipolysis in humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1996
- A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency.Journal of Clinical Endocrinology & Metabolism, 1996
- Effect of Human Growth Hormone on Muscle and Adipose Tissue Metabolism in the Forearm of Man *JCI Insight, 1965